News
Elston’s Bruce Williams discuss ResMed's results and margin momentum, and whether the stock still deserves a buy rating.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback